During our session, we highlighted key trends in formulation strategies, scalability, and performance optimization and discussed how advances in nanoparticle technologies are shaping both academic research and industrial applications. The exchange underscored the growing importance of interdisciplinary collaboration in translating innovative formulations from the lab into real-world solutions.

We recently attended the International mRNA Health Conference, a leading forum bringing together experts from academia and industry to discuss the latest advances in mRNA science and applications. The event provided valuable insights into emerging technologies, delivery strategies, and translational approaches shaping the future of RNA-based solutions.

The conference offered an excellent platform for discussing collaboration opportunities, market developments, and innovative approaches shaping the future of biotechnology. Events like BIO-Europe play a key role in fostering meaningful partnerships and accelerating progress across the industry.

The visit provided a valuable opportunity for an in-depth exchange on academic training, innovation, and the critical role of close collaboration between universities and industry.

At NovoArc, we strongly believe that bridging academic knowledge with applied research and industrial practice is essential for driving meaningful innovation in biotechnology. Hosting students and maintaining an active dialogue with academic partners allows us to contribute to talent development while also benefiting from fresh perspectives and emerging scientific ideas.

We would like to thank Prof. Klausgraber for the insightful discussion and his visit, and we extend our appreciation to Ema for her dedication and excellent work. We look forward to continuing to strengthen our collaboration with academic institutions and supporting the next generation of biotech professionals.

CPHI Frankfurt provided an excellent platform for strategic discussions, partnership exploration, and staying closely aligned with the evolving needs of the global pharma industry.

See you at CPHI Milan 2026!

As part of the program, we delivered a presentation outlining our strategic focus, core capabilities, and market approach within the biotech sector. The session emphasized how applied technologies, scalable solutions, and industry-driven collaboration can accelerate the translation of innovation into commercially viable outcomes.

The summit provided valuable opportunities for business-focused discussions, partnership exploration, and alignment with stakeholders shaping the future of biotechnology in Austria and beyond. Events like the Biotech Austria Summit play an important role in strengthening the interface between technology development, market needs, and sustainable growth.

Over the past four years, we’ve transformed fundamental research into real-world impact, developing lipid systems that protect active pharmaceutical ingredients from degradation, enhance bioavailability, and expand formulation possibilities.

As we celebrate our 4th anniversary, we take pride in the progress made and the partnerships that have fueled our growth. Together with our collaborators, we are committed to advancing the next generation of therapeutics, bridging science and application to create safer, more effective treatments for patients worldwide.

We were honored to welcome Federal Minister Dr. Wolfgang Hattmannsdorfer, Bundesvorsitzende der Jungen Wirtschaft Bettina Dorfer-Pauschenwein, and their teams from the Federal Ministry for Economic Affairs and Energy and the Austrian Federal Economic Chamber to NovoArc GmbH. We opened our doors to showcase our proprietary archaeal lipid technology, state-of-the-art laboratories, and the team behind our innovation.

Together, we explored how Austria can evolve from a nation of strong research excellence into a global market leader by fostering translational capabilities, scaling manufacturing capacity, and encouraging cross-border collaborations. Strengthening commercialization pathways and venture support for emerging biotech companies was identified as key to bridging the gap between the lab and the global marketplace.

During the visit, we also presented our product portfolio demonstrating how our lipid systems enhance stability, bioavailability, and formulation flexibility for next-generation therapeutics. The future of biotech innovation depends on people. We reflected on how Austria can nurture a new generation of talent with the interdisciplinary skills essential for bioprocessing, data-driven biotechnology, and analytical platforms. As a company committed to bridging science and application, we take pride in contributing to Austria’s growing biotech ecosystem transforming fundamental research into impact, one breakthrough at a time.